Combination therapy in multiple sclerosis

@article{Milo2011CombinationTI,
  title={Combination therapy in multiple sclerosis},
  author={Ron Milo and Hillel S. Panitch},
  journal={Journal of Neuroimmunology},
  year={2011},
  volume={231},
  pages={23-31}
}
The multifaceted pathogenesis of multiple sclerosis (MS) involves complex interactions between the immune and the central nervous systems which provide a multitude of targets for therapeutic interventions. Current therapies for MS are only partially effective. One potential strategy to increase treatment efficacy is the combination of two or more drugs with complementary mechanisms of action, which may result in additive or synergistic therapeutic effects. In this review, we discuss the… 
View on Elsevier
doi.org
15 Citations
Background Citations
2
Methods Citations
1
Results Citations
1

15 Citations

Citation Type

Citation Type

Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs
  • R. Milo
  • Medicine
    Expert opinion on pharmacotherapy
  • 2015
TLDR
The mode of action and main characteristics of current immunomodulatory drugs for MS and their place in the therapeutic algorithm of the disease based on evidence from clinical trials are described, paving the road for personalized medicine in MS.
Evolution of clinical trials in multiple sclerosis
TLDR
The replacement of the placebo arm by an active comparator arm in trials have raised the cost of trials by requiring larger sample sizes to detect on-study changes in treatment effects, and efforts to improve trial efficiency in RRMS have focused on exploring adaptive designs and relying on sensitive magnetic resonance imaging measures of disease activity.
Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview
TLDR
New findings regarding drugs with immunomodulatory, neuroprotective or regenerative properties and possible treatment strategies for secondary progressive multiple sclerosis are discussed.
A case of multiple sclerosis improvement following removal of heavy metal intoxication
TLDR
The case report suggests that levels of toxic metals can be tested in patients affected by neurodegenerative diseases as MS, and suggests that improved symptoms suggestive of MS remission can be revealed.
Prediction of combination therapies based on topological modeling of the immune signaling network in multiple sclerosis
TLDR
A network-based modeling approach based on phosphoproteomic data uncovered features of healthy-, disease- and drug-specific signaling networks and predicted several combinations with approved MS drugs that could revert signaling to a healthy-like state.
Network analysis of randomized controlled trials in multiple sclerosis.
Prediction of combination therapies based on topological modeling of the immune signaling network in Multiple Sclerosis
TLDR
A network-based modeling approach based on phosphoproteomic data upon perturbation with ligands and drugs of healthy donors and MS patients to create donor-specific models that predict several combinations with approved MS drugs.
Teriflunomide added to interferon-&bgr; in relapsing multiple sclerosis: A randomized phase II trial
TLDR
This study provides Class II evidence that teriflunomide, 7 and 14 mg, added to IFN&bgr;, is safe and reduced MRI disease activity compared with IFN & bgr; alone.
Multiple sclerosis in Kashmir: Where we stand
Alterations in the cholinesterase and adenosine deaminase activities and inflammation biomarker levels in patients with multiple sclerosis
TLDR
The results suggest that alterations in the biomarkers of inflammation and hydrolysis of nucleotides and nucleosides may contribute to the understanding of the neurological dysfunction of RRMS patients.
...
1
2
...

References

SHOWING 1-10 OF 87 REFERENCES
Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis
TLDR
It is demonstrated that the combination of these drugs suppresses EAE severity and provides neuroprotection thereby suggesting that this pharmacological approach could be a better future therapeutic strategy to treat MS patients.
Review: Innovative monoclonal antibody therapies in multiple sclerosis
TLDR
The data available from these recent phase II trials are reviewed and the results may not only broaden therapeutic options in the near future, but also provide new insights into disease pathogenesis.
The mechanism of action of methylprednisolone in the treatment of multiple sclerosis
TLDR
The most recent observations on methylprednisolone mechanisms both to understand the disease mechanism and to design treatment regimes that are more specific towards both the individual and the disease state are reviewed.
Oral simvastatin treatment in relapsing-remitting multiple sclerosis
TLDR
Investigation of use of oral simvastatin in 30 individuals with relapsing-remitting multiple sclerosis found it to inhibit inflammatory components of multiple sclerosis that lead to neurological disability.
Combined treatment with atorvastatin and minocycline suppresses severity of EAE
Emerging multiple sclerosis oral therapies
TLDR
Fingolimod, a novel immunosuppressant, significantly lowered annual relapse rates in phase II/III trials and teriflunomide, an immunomodulator, significantly reduced MRI lesion activity and reduced annual relapse Rates in a phase II trial.
Additive effect of the combination of glatiramer acetate and minocycline in a model of MS
TLDR
It is described that the tetracycline derivative, minocycline, attenuates the severity of experimental autoimmune encephalomyelitis (EAE), a model of MS, and this combination resulted in a significant reduction of disease severity and disease burden.
Effective combination of minocycline and interferon-β in a model of multiple sclerosis
TLDR
Results suggest the utility of the combination of minocycline and interferon-beta in MS, as used at sub-optimal doses.
Diverse Targets for Intervention during Inflammatory and Neurodegenerative Phases of Multiple Sclerosis
TLDR
A greater diversity of cell types and molecules involved in MS is now evident and remyelination can occur during the early inflammatory phase when damage may be reversible, it is impaired in the later stages, which involve axonal death.
Concepts of induction and escalation therapy in multiple sclerosis
  • P. Rieckmann
  • Medicine
    Journal of the Neurological Sciences
  • 2009
...
1
2
3
4
5
...